I am distressed by your coverage of innovative therapies, such as dual HER2 blockade (see The ASCO Post, January 1, 2012, and Supplement to February 15, 2012), without mentioning that these therapies will never be cost-effective given the current pricing of the agents involved. If we wish to maintain our credibility as the arbiters of appropriate cancer therapy, we cannot continue to ignore the elephant in the room.
ASCO has to come out strongly in favor of negotiated pricing for new cancer drugs rather than the current “take it or leave it” system. The current cost structure of new drugs is unsustainable, and we, as leaders, need to say it, and say it loudly. ■
—Michael J Kraut, MD
Medical Director, Oncology
Providence Cancer Institute
Women with HER2-positive advanced breast cancer are much less likely to have disease progression or die when two agents are used instead of one to target the HER2 signaling pathway, investigators for the international phase III CLEOPATRA trial found.
The 808 women studied were randomly assigned to ...
There is an emerging theme in HER2-positive breast cancer: The greater the pathway inhibition, the better the outcome. The latest evidence comes from the phase III Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) trial of 808 patients with previously untreated metastatic disease. The...